IBD and Biomarkers: What You Need to Know With Andres Hurtado-Lorenzo, PhD

What if we knew which patients would have severe Crohn’s disease or ulcerative colitis? And which wouldn’t? How about if we could tell which drug would work best in which patient? Knowing these things would change how inflammatory bowel disease (IBD) is diagnosed and treated. Plus, more importantly: it would improve lives. Dr Andres Hurtado-Lorenzo, Vice President of Translational research and IBD Ventures at the Crohn's and Colitis Foundation explains biomarkers and how they may play into the future of how IBD is diagnosed, managed, and treated.

Resources:

• Crohn’s & Colitis Foundation:https://www.crohnscolitisfoundation.org/
• IBD Plexus:https://www.crohnscolitisfoundation.org/research/current-research-initiatives/ibd-plexus/about
• RISK Study:https://www.crohnscolitisfoundation.org/research/current-research-initiatives/pediatric-risk-stratification
• IBD Ventures:https://www.crohnscolitisfoundation.org/research/grants-fellowships/entrepreneurial-investing/portfolio
• Olink: https://www.olink.com
• Foundation for the National Institutes of Health: https://www.fnih.org
• Genedata: https://www.com
• Glycominds: https://www.glycominds.com/blood-tests-1
• PredictImmune:https://www.predictimmune.com/

Research:

• Honig G, Heller C, Hurtado-Lorenzo A. Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2020;26(10):1451-1462. doi:10.1093/ibd/izaa210. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500521/pdf/izaa210.pdf
• Honig G, Larkin PB, Heller C, Hurtado-Lorenzo A. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021;27(Suppl 2):S1-S16. doi:10.1093/ibd/izab230. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922161/pdf/izab230.pdf
• Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710-1718. doi:10.1016/S0140-6736(17)30317-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719489/pdf/nihms923305.pdf
• Biasci D, Lee JC, Noor NM, et al. A blood-based prognostic biomarker in IBD. Gut. 2019;68(8):1386-1395. doi:10.1136/gutjnl-2019-318343. https://www.predictimmune.com/wp-content/uploads/2020/09/Biasci-et-al-A-blood-based-prognostic-biomarker-in-IBD-Gut-2019.pdf
• de Bruyn M, Ringold R, Martens E, et al. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. J Crohns Colitis. 2020;14(2):176-184. doi:10.1093/ecco-jcc/jjz125. https://doi.org/10.1093/ecco-jcc/jjz125

Find Amber J Tresca at:

• AboutIBD.com: http://aboutibd.com/
• Verywell: https://www.verywell.com/ibd-crohns-colitis-4014703
• Facebook: https://www.facebook.com/aboutIBD
• Twitter: https://twitter.com/aboutIBD
• Pinterest: https://www.pinterest.com/aboutibd/
<